Literature DB >> 29937003

Patterns of opioid use and prescribing for outpatient anorectal operations.

Abhishek Swarup1, Kristina A Mathis2, Maureen V Hill1, Srinivas Joga Ivatury3.   

Abstract

BACKGROUND: Surgery for anorectal diseases is thought to cause significant pain postoperatively. There is little known regarding standardized opioid-prescribing trends and patient use following surgery for anorectal diseases. We aimed to evaluate and analyze opioid-prescribing trends and patient use for outpatient anorectal operations.
MATERIALS AND METHODS: All patients who underwent outpatient anorectal surgery performed over a 1-y period at a single institution were eligible. Procedures included hemorrhoidectomy, anal fistula repair/seton, anal fissure treatment with sphincterotomy, and transanal excision of rectal tumors. Demographic, operative, and postoperative data were obtained. Patients were given a survey to determine postoperative pain control with opioid and non-narcotic analgesia use; respondents were included in analysis.
RESULTS: Forty-two outpatient anorectal surgery patients were included: 13 had hemorrhoidectomy, 22 had anal fistula repair/seton, one had sphincterotomy, and six had transanal excisions. All patients had multimodality treatment with either an anal block and/or postoperative nonopioid analgesics. Ninety percent were prescribed opioids postoperatively with a median of 20 pills (range: 0-120 pills). Forty-three percent (18/42) did not fill their prescription. For those who used opioids, the median number of pills taken was four. Eighty percent of pills prescribed were not used. One patient required a refill. Greater than 60% of respondents reported good to excellent pain control on a five-point scale.
CONCLUSIONS: Most patients had adequate pain control after anorectal surgery with little to no use of opioids and that more than 80% of opioid pills prescribed were not consumed. We intend to standardize our prescribing opioid quantities for outpatient anorectal operations to reflect this reduced use.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anorectal; Opioid; Prescribing patterns; Surgery

Mesh:

Substances:

Year:  2018        PMID: 29937003     DOI: 10.1016/j.jss.2018.04.005

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  6 in total

1.  Reduction of Opioid Overprescribing and Use Following Standardized Educational Intervention: A Survey of Patient Experiences Following Anorectal Procedures.

Authors:  Dong Hum Yoon; Kasim L Mirza; Carey J Wickham; Erik R Noren; Jason Chen; Sang W Lee; Kyle G Cologne; Glenn T Ault
Journal:  Dis Colon Rectum       Date:  2021-09-01       Impact factor: 4.412

2.  Health Care Costs and Resource Utilization Among Patients With Crohn's Disease With and Without Perianal Fistula.

Authors:  Grace Chen; Vasantha Pedarla; Kyle D Null; Susan E Cazzetta; Qasim Rana Khan; David A Schwartz
Journal:  Inflamm Bowel Dis       Date:  2022-06-03       Impact factor: 7.290

3.  A national evaluation of opioid prescribing and persistent use after ambulatory anorectal surgery.

Authors:  Deborah S Keller; Brooke C Kenney; Calista M Harbaugh; Jennifer F Waljee; Chad M Brummett
Journal:  Surgery       Date:  2020-12-04       Impact factor: 3.982

Review 4.  A Pathway for Developing Postoperative Opioid Prescribing Best Practices.

Authors:  Ryan Howard; Joceline Vu; Jay Lee; Chad Brummett; Michael Englesbe; Jennifer Waljee
Journal:  Ann Surg       Date:  2020-01       Impact factor: 13.787

5.  Leftover opioids following adult surgical procedures: a systematic review and meta-analysis.

Authors:  Lori Schirle; Amanda L Stone; Matthew C Morris; Sarah S Osmundson; Philip D Walker; Mary S Dietrich; Stephen Bruehl
Journal:  Syst Rev       Date:  2020-06-11

6.  Overprescription of Opioids Following Outpatient Anorectal Surgery: A Single-Institution Study.

Authors:  Devon Livingston-Rosanoff; Taylor Aiken; Brooks Rademacher; Christopher Glover; Paul Skelton; Marissa Paulson; Elise H Lawson
Journal:  Dis Colon Rectum       Date:  2020-11       Impact factor: 4.585

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.